ARMO BioSciences, Inc. (ARMO) Touches $27.10 Low on Apr, 17; Southern Missouri Bancorp (SMBC)’s Sentiment Is 2.11

April 17, 2018 - By Peter Erickson

Southern Missouri Bancorp, Inc. (NASDAQ:SMBC) Logo

The stock of ARMO BioSciences, Inc. (NASDAQ:ARMO) reached all time low today, Apr, 17 and still has $25.75 target or 5.00% below today’s $27.10 share price. This indicates more downside for the $823.98M company. This technical setup was reported by If the $25.75 PT is reached, the company will be worth $41.20M less. The stock decreased 7.06% or $2.06 during the last trading session, reaching $27.1. About 375,303 shares traded or 19.56% up from the average. ARMO BioSciences, Inc. (NASDAQ:ARMO) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Southern Missouri Bancorp Inc (SMBC) investors sentiment decreased to 2.11 in Q4 2017. It’s down -1.89, from 4 in 2017Q3. The ratio has dropped, as 38 funds increased or started new equity positions, while 18 sold and trimmed equity positions in Southern Missouri Bancorp Inc. The funds in our database now hold: 4.11 million shares, down from 7.89 million shares in 2017Q3. Also, the number of funds holding Southern Missouri Bancorp Inc in top ten equity positions was flat from 3 to 3 for the same number . Sold All: 5 Reduced: 13 Increased: 24 New Position: 14.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $336,610 activity.

Raffles Associates Lp holds 10.51% of its portfolio in Southern Missouri Bancorp, Inc. for 265,958 shares. Jacobs Asset Management Llc owns 537,829 shares or 3.83% of their US portfolio. Moreover, Fj Capital Management Llc has 3.2% invested in the company for 679,600 shares. The New York-based Maltese Capital Management Llc has invested 0.17% in the stock. Smith Moore & Co., a Missouri-based fund reported 12,326 shares.

Southern Missouri Bancorp, Inc. operates as the bank holding firm for Southern Bank that provides banking and financial services to individuals and corporate clients in the United States. The company has market cap of $334.06 million. It offers various deposit instruments, including demand deposit accounts, negotiable order of withdrawal accounts, money market deposit accounts, saving accounts, certificates of deposit, and retirement savings plans. It has a 17.08 P/E ratio. The firm also provides loans for the acquisition or refinance of one-to four-family residences; loans secured by commercial real estate, including land, shopping centers, retail establishments, nursing homes and other healthcare related facilities, and other businesses; construction loans; and various secured consumer loans comprising home equity, direct and indirect automobile loans, second mortgages, mobile home loans, and loans secured by deposits.

The stock increased 1.72% or $0.63 during the last trading session, reaching $37.23. About 3,318 shares traded. Southern Missouri Bancorp, Inc. (SMBC) has risen 8.61% since April 17, 2017 and is uptrending. It has underperformed by 2.94% the S&P500.

Analysts await ARMO BioSciences, Inc. (NASDAQ:ARMO) to report earnings on July, 2. After $-9.62 actual EPS reported by ARMO BioSciences, Inc. for the previous quarter, Wall Street now forecasts -95.01% EPS growth.

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. The company has market cap of $823.98 million. The Company’s lead product candidate includes AM0010, a drug that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma and chemotherapy. It currently has negative earnings. The firm is also developing AM0010 with anti-PD-1 immune checkpoint inhibitor that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, as well as that is in Phase I/Ib clinical trial for the treatment of renal cell carcinoma, and melanoma and other solid tumors.

Southern Missouri Bancorp, Inc. (NASDAQ:SMBC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: